273 related articles for article (PubMed ID: 23901839)
21. Infliximab regulates monocytes and regulatory T cells in Kawasaki disease.
Koizumi K; Hoshiai M; Katsumata N; Toda T; Kise H; Hasebe Y; Kono Y; Sunaga Y; Yoshizawa M; Watanabe A; Kagami K; Abe M; Sugita K
Pediatr Int; 2018 Sep; 60(9):796-802. PubMed ID: 29543362
[TBL] [Abstract][Full Text] [Related]
22. Infliximab plus plasma exchange rescue therapy in Kawasaki disease.
Sonoda K; Mori M; Hokosaki T; Yokota S
J Pediatr; 2014 May; 164(5):1128-1132.e1. PubMed ID: 24560183
[TBL] [Abstract][Full Text] [Related]
23. [Anti TNF-α (infliximab) treatment for intravenous immunoglobulin (IVIG) resistance patients with acute Kawasaki disease the effects of anticytokine therapy].
Saji T; Takatsuki S; Kobayashi T
Nihon Rinsho; 2014 Sep; 72(9):1641-9. PubMed ID: 25518416
[TBL] [Abstract][Full Text] [Related]
24. Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease.
Chan H; Chi H; You H; Wang M; Zhang G; Yang H; Li Q
BMC Pediatr; 2019 May; 19(1):158. PubMed ID: 31101091
[TBL] [Abstract][Full Text] [Related]
25. Intravenous immunoglobulin induces IgG internalization by tolerogenic myeloid dendritic cells that secrete IL-10 and expand Fc-specific regulatory T cells.
Hsieh LE; Song J; Tremoulet AH; Burns JC; Franco A
Clin Exp Immunol; 2022 Jun; 208(3):361-371. PubMed ID: 35536993
[TBL] [Abstract][Full Text] [Related]
26. High Dose Intravenous IgG Therapy Modulates Multiple NK Cell and T Cell Functions in Patients With Immune Dysregulation.
McAlpine SM; Roberts SE; Heath JJ; Käsermann F; Issekutz AC; Issekutz TB; Derfalvi B
Front Immunol; 2021; 12():660506. PubMed ID: 34093549
[TBL] [Abstract][Full Text] [Related]
27. Characterization of circulating immune cells in acute Kawasaki disease suggests exposure to different antigens.
Burns JC; Hsieh LE; Kumar J; Behnamfar N; Shimizu C; Sivilay N; Tremoulet AH; Franco A
Clin Exp Immunol; 2020 Dec; 202(3):263-272. PubMed ID: 32812215
[TBL] [Abstract][Full Text] [Related]
28. Specificity of regulatory T cells that modulate vascular inflammation.
Franco A; Touma R; Song Y; Shimizu C; Tremoulet AH; Kanegaye JT; Burns JC
Autoimmunity; 2014 Mar; 47(2):95-104. PubMed ID: 24490882
[TBL] [Abstract][Full Text] [Related]
29. Lack of CD4⁺CD25⁺FOXP3⁺ regulatory T cells is associated with resistance to intravenous immunoglobulin therapy in patients with Kawasaki disease.
Hirabayashi Y; Takahashi Y; Xu Y; Akane K; Villalobos IB; Okuno Y; Hasegawa S; Muramatsu H; Hama A; Kato T; Kojima S
Eur J Pediatr; 2013 Jun; 172(6):833-7. PubMed ID: 23340699
[TBL] [Abstract][Full Text] [Related]
30. TNF-α is superior to conventional inflammatory mediators in forecasting IVIG nonresponse and coronary arteritis in Chinese children with Kawasaki disease.
Hu P; Jiang GM; Wu Y; Huang BY; Liu SY; Zhang DD; Xu Y; Wu YF; Xia X; Wei W; Hu B
Clin Chim Acta; 2017 Aug; 471():76-80. PubMed ID: 28526535
[TBL] [Abstract][Full Text] [Related]
31. Current knowledge of TNF-α monoclonal antibody infliximab in treating Kawasaki disease: a comprehensive review.
Chen J; Liao J; Xiang L; Zhang S; Yan Y
Front Immunol; 2023; 14():1237670. PubMed ID: 37936712
[TBL] [Abstract][Full Text] [Related]
32. Infliximab treatment for refractory Kawasaki syndrome.
Burns JC; Mason WH; Hauger SB; Janai H; Bastian JF; Wohrley JD; Balfour I; Shen CA; Michel ED; Shulman ST; Melish ME
J Pediatr; 2005 May; 146(5):662-7. PubMed ID: 15870671
[TBL] [Abstract][Full Text] [Related]
33. Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease.
Vande Casteele N; Oyamada J; Shimizu C; Best BM; Capparelli EV; Tremoulet AH; Burns JC
Clin Pharmacokinet; 2018 Dec; 57(12):1593-1601. PubMed ID: 29623653
[TBL] [Abstract][Full Text] [Related]
34. Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease.
Hirono K; Kemmotsu Y; Wittkowski H; Foell D; Saito K; Ibuki K; Watanabe K; Watanabe S; Uese K; Kanegane H; Origasa H; Ichida F; Roth J; Miyawaki T; Saji T
Pediatr Res; 2009 Jun; 65(6):696-701. PubMed ID: 19430379
[TBL] [Abstract][Full Text] [Related]
35. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
Burns JC; Roberts SC; Tremoulet AH; He F; Printz BF; Ashouri N; Jain SS; Michalik DE; Sharma K; Truong DT; Wood JB; Kim KK; Jain S;
Lancet Child Adolesc Health; 2021 Dec; 5(12):852-861. PubMed ID: 34715057
[TBL] [Abstract][Full Text] [Related]
36. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease.
Samadli S; Liu FF; Mammadov G; Wang JJ; Liu HH; Wu YF; Luo HH; Wu Y; Chen WX; Zhang DD; Wei W; Hu P
Pediatr Rheumatol Online J; 2019 Jul; 17(1):53. PubMed ID: 31366406
[TBL] [Abstract][Full Text] [Related]
37. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
Lei WT; Chang LS; Zeng BY; Tu YK; Uehara R; Matsuoka YJ; Su KP; Lee PC; Cavalcante JL; Stubbs B; Lin PY; Wu YC; Hsu CW; Chen TY; Chen YW; Yeh PY; Sun CK; Tseng PT; Kao YH
EBioMedicine; 2022 Apr; 78():103946. PubMed ID: 35306339
[TBL] [Abstract][Full Text] [Related]
38. Dynamics of immunocyte activation during intravenous immunoglobulin treatment in Kawasaki disease.
Matsuguma C; Wakiguchi H; Suzuki Y; Okada S; Furuta T; Ohnishi Y; Azuma Y; Ohga S; Hasegawa S
Scand J Rheumatol; 2019 Nov; 48(6):491-496. PubMed ID: 31272272
[No Abstract] [Full Text] [Related]
39. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H; He Y; Rong X; Ren Y; Pan L; Chu M; Wu R; Shi H
Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
[TBL] [Abstract][Full Text] [Related]
40. Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis.
Miyata K; Bainto EV; Sun X; Jain S; Dummer KB; Burns JC; Tremoulet AH
Arch Dis Child; 2023 Oct; 108(10):833-838. PubMed ID: 37258054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
